연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3485. Dynamic insights into infection risk over time in two-stage implant-based breast reconstruction: a retrospective cohort study
Ha JH, Ahn S, Kim HK, Lee HB, Moon HG, Han W, Hong KY, Chang H, Lee GK, Choi J, Jin US.
Int J Surg. 2024 Jun 1;110(6):3433-3439.
Link
3484. Disruption of G-quadruplex dynamicity by BRCA2 abrogation instigates phase separation and break-induced replication at telomeres
Lee JJ, Kim H, Park H, Lee U, Kim C, Lee M, Shin Y, Jung JJ, Lee HB, Han W, Lee H.
Nucleic Acids Res. 2024 Jun 10;52(10):5756-5773.
Link
3483. Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project
Potter S, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, Dubsky P, Iwata H, Jiang M, Lee HB, MacKenzie M, Poulakaki F, Richardson AL, Sepulveda K, Spillane A, Thompson AM, Werutsky G, Wright JL, Zdenkowski N, Cowan K, McIntosh S.
BMJ Open. 2024 Apr 19;14(4):e084488.
Link
3482. Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review
Jiang M, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, Dubsky P, Finestone S, Iwata H, Lee HB, MacKenzie M, Meyn A, Poulakaki F, Richardson AL, Sepulveda K, Spillane A, Thompson AM, Werutsky G, Wright JL, Zdenkowski N, Cowan K, McIntosh SA, Potter S.
Eur J Surg Oncol. 2024 Oct;50(10):108554.
Link
3481. Age and Late Recurrence in Young Patients With ER-Positive, ERBB2-Negative Breast Cancer
Shin DS, Lee J, Kang E, Noh D, Cheun JH, Lee JH, Son Y, Bae SJ, Kim SW, Lee JE, Yu J, Chae BJ, Kwon S, Lee HB, Ahn SG, Ryu JM.
JAMA Netw Open. 2024 Nov 4;7(11):e2442663.
Link
3480. Prognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results
Kang E, Cheun JH, Lee J, Koh J, Lee H, Park JY, Lee HJ, Kang B, Park WK, Son J, Kim B, Chung W, Han W, Lee HB, Lee SB, Ryu JM.
Cancer Res Treat. 2024 Dec 23.
Link
3479. Anti-SARS-CoV-2 Nucleocapsid Antibody Positivity Three Years after COVID-19
Chang Kyung Kang 1, Youngju Kim 2 3, Hyeon Jae Jo 1, Chan Mi Lee 1, Nam Joong Kim 1, Chang-Han Lee 2 3 4 5 6, Pyoeng Gyun Choe 1, Wan Beom Park 1, Myoung-Don Oh 1
Jpn J Infect Dis. 2024 Sep 19;77(5):285-288.
Link
3478. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.
Noguchi E, Yamanaka T, Mukai H, Yamamoto N, Chung CF, Lu YS, Chang DY, Sohn J, Kim GM, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Sudo K, Kojima Y, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K.
NPJ Breast Cancer. 2024 Aug 22;10(1):76. d
Link
3477. Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
Park C, Suh KJ, Kim SH, Lee KH, Im SA, Kim MH, Sohn J, Jeong JH, Jung KH, Lee KE, Park YH, Kim HJ, Cho EK, Choi IS, Noh SJ, Shin I, Cho DY, Kim JH
Cancer immunology, immunotherapy : CII 2024 Aug 6;73(10):197.
Link
3476. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study
Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Han W, Im SA, Tan VKM, Phyu N, Wong FY, Tan PH, Yap YS
Journal of the National Comprehensive Cancer Network : JNCCN 2024 May 14;22(2D):e237121.
Link